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S U M M A R Y
Staphylococcus aureus is a well adapted human pathogen, capable of living freely in the inanimate
environment and spreading from person to person, existing as a colonizer or commensal, hiding in
intracellular compartments and, most importantly, inducing various forms of human disease.
Infections caused by S. aureus, above all by antibiotic-resistant strains, have reached epidemic
proportions globally. The overall burden of staphylococcal disease caused by antibiotic-resistant S.
aureus, particularly by themethicillin-resistant strains, is increasing inmany countries, including Italy,
in both healthcare and community settings. The widespread use of antibiotics has undoubtedly
accelerated the evolution of S. aureus, which, acquiring multiple resistance genes, has become able to
survive almost all antibiotic families; this evolution versus more resistant phenotypes has continued
among the newer agents, including linezolid and daptomycin. The diminished clinical usefulness of
vancomycin is seen as one of the most worrisome problems in many clinical settings and in many
countries. In fact, the increasing spread of heteroresistant vancomycin-intermediate S. aureus (hVISA)
and vancomycin intermediate (VISA) strains adds new problems, not only in terms of the treatment of
severe infections sustained by these microorganisms, but also in the microbiological deﬁnition of
susceptibility.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Staphylococcus aureus is a well adapted human pathogen and
infections caused by this microorganism, above all by antibiotic-
resistant strains, have reached epidemic proportions globally. The
rising prevalence of nosocomial methicillin-resistant S. aureus
(MRSA) and the recent emergence of community-acquired MRSA
(CA-MRSA) are major clinical, public health, and economic
challenges.
MRSA is a multidrug-resistant pathogen, but the recent
evidence that glycopeptides are losing their potency, is particularly
worrisome. Serious infections due to MRSA, deﬁned as susceptible
using standard routine tests, are not responding well to
glycopeptides. The emergence of heteroresistant vancomycin-
intermediate S. aureus (hVISA) adds new problems, not only in
terms of the treatment of severe infections sustained by these
microorganisms, but also in the microbiological deﬁnition of
susceptibility.* Corresponding author. Tel.: +39 095 2504714; fax: +39 095 2504733.
E-mail address: stefanis@unict.it (S. Stefani).
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doi:10.1016/j.ijid.2010.05.0092. Pathogenesis and epidemiology
S. aureus is a well adapted human pathogen, capable of living
freely in the inanimate environment and spreading from person to
person, existing as a colonizer or commensal, hiding in intracellu-
lar compartments and, most importantly, inducing various forms
of human disease. Additionally, staphylococcimay formbioﬁlms in
any of their different states of existence.
A fundamental biological property of S. aureus is its ability to
asymptomatically colonize healthy individuals. Approximately
30% of humans are nasal carriers,1 such that, in these individuals,
the microorganism is part of the normal ﬂora. S. aureus carriers are
at higher risk of infections and they are presumed to be an
important source of the S. aureus strains that spread among
individuals. Nasal colonization rates by S. aureus among hospital-
ized patients are comparable to those of the general population.
However, MRSA carriage among the general population is less than
1%,2 whereas S. aureus (MRSA) prevalence in nosocomial bacter-
emia is over 50% in certain countries.3 The primary mode of
transmission of this organism is by direct contact, usually skin-to-
skin contact, and various host factors can predispose individuals to
infection, including the loss of the normal skin barrier, theses. Published by Elsevier Ltd. All rights reserved.
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defects in neutrophil function. To these factors, antibiotic pressure,
length of stay in an intensive care unit (ICU), colonization pressure,
professional healthcare workload, hand hygiene levels, isolation
treatment measures, and environmental contamination have been
proposed as important factors in the acquisition and transmission
of S. aureus in ICUs.4
Infections caused by S. aureus, above all by antibiotic-resistant
strains, have reached epidemic proportions globally.5 The capacity
of this microorganism to cause a spectrum of human disease
reﬂects an incredible ability to adapt to microenvironments in the
human body and suggests that the pathogenesis of S. aureus is a
complex, regulated process, as summarized below, involving a
diverse array of determinants coordinately expressed at different
stages of infection.6 As described before, staphylococcal pathogen-
esis is multifactorial, involving three classes of factors accounting
for approximately 100: secreted proteins, including superantigens,
cytotoxin and tissue degrading enzymes; cell-surface bound
proteins (MSCRAMMs, i.e., microbial surface components recog-
nizing adhesive matrix molecules), including ﬁbrinogen binding
protein, other adhesins and anti-opsonins; and cell surface
proteins, including the polysaccharide capsule and components
of the cell wall peptidoglycan.7
The classic staphylococcal infection is an abscess: organisms
entering the tissue of a host produce a series of extracellular
proteins and other factors, such as cell wall and capsular
components, which enable them to coagulate ﬁbrinogen, adhere
to the intercellular matrix, degrade tissue components, and lyse
local cellular elements. This evokes a potent innate immune
response that includes interleukins, opsonins, complement, and
phagocytes. Additionally, humans have circulating antibodies to
most staphylococcal antigens, and these will obviously participate
in the initial response. These antibodies, the innate immune
response, and ﬁbrin generated by the organism, wall off the lesion
creating a pocket within which a battle between the organism and
phagocytes is waged, generating pus.
Although everyone gets superﬁcial skin infections, staphylo-
coccal infections can be initiated occasionally in deep tissue sites
and these result in deep tissue infections that often require
surgery. S. aureus can also alight on the heart valves, more often in
intravenous drug abusers or the elderly. Heart valve lesions, known
as vegetations, consist largely of platelets, ﬁbrin organisms, and
neutrophils and their structure is considered akin to bioﬁlm
formed on inanimate surfaces. A particularly troublesome, but
non-fatal, condition is osteomyelitis, which again can occasionally
occur spontaneously, but much more often follows an open
fracture.
A special set of pathological conditions, toxinoses, are caused by
single toxins. In many cases, the puriﬁed toxin can generate all the
symptoms; in some cases, the living organism must be present,
contributing, for example, to the ability to adhere to the
extracellular matrix or to resist eradication by the host. Examples
are toxic shock syndrome (TSS), scalded skin syndrome, and
necrotizing pneumonia (Panton–Valentine leukocidin (PVL)).
Such a complex and integrated set of weapons of virulence
genes suggests that distinct networks of virulence genes are likely
activated in response to host signals; in vitro results have
demonstrated regulation in a population density manner under
the control of global regulators such as the agr system.8 Knowledge
of which genes are turned on and the circumstances under which
they are activated is critical for understanding their role in
pathogenesis. Much has been learned from the in vitro analyses
and from animalmodel studies, but recent data on the applicability
of these models to human disease are opening a new era of
conﬁrmation of what is known to date and will probably bring
about new strategies to treat serious staphylococcal infections.9The overall burden of staphylococcal disease caused by
antibiotic-resistant S. aureus, above all by the methicillin-resistant
strains, is increasing in many countries, including Italy, in both
healthcare and community settings.10,11 In a recent American
update by the National Healthcare Safety Network (NHNS)12
performed on antimicrobial-resistant organisms responsible for
healthcare-associated infections, S. aureus was the most prevalent
isolate in skin and soft tissue infections (SSTIs), in blood stream
infections (BSI), and in ventilator-associated pneumonia (VAP); in
the case of surgical site infections its prevalence changed as
follows: neurologic < orthopedic< cardiac< vascular< obstetric/
gynecological. The authors found an overall MRSA prevalence of
56.2% and their data were comparable to data from other
surveillance systems in the USA and Europe.3,12,13
It is clear that MRSA is still the number one cause of hospital-
associated infections. The mortality rate associated with invasive
infections is approximately 20%14 and in the USA, but also in some
countries in Europe, these infections are probably the leading
cause of death by any single agent; fatalities resulting from these
infections are estimated to surpass those caused by HIV/AIDS.14
The recent appearance of CA-MRSA, i.e., infections that occur
outside of healthcare facilities in otherwise healthy people, is one
of the most surprising events in recent years and adds to our
concerns.11,15 In general CA-MRSA is particularly virulent com-
pared to HA-MRSA due to the presence ofmany virulence factors.16
It primarily causes SSTIs, but invasive, fatal infections such as
bacteremia and necrotizing pneumonia have also been reported.
These strains are also well characterized by genetic markers such
as the presence of SCCmec type IV, V or VII and the presence of the
PVL. It still remains a mystery why these antibiotic-resistant
bacteria have emerged in a niche such as the community, not under
the high selective pressure exerted by antibiotics, but the success
of these clones is demonstrated by their rapid spread, and, in
recent years, by the possible permeation into hospitals of these
new more virulent CA-MRSA strains.10,14
3. History of MRSA and evolution of resistance
The history of the epidemic behavior of S. aureus starts in the
‘antibiotic era’ immediately following the introduction of penicillin
in the 1940s; during the 1950s, the notorious penicillin-resistant
clone of S. aureus, known as phage type 80/81, PVL producer,
emerged and caused serious hospital-acquired (HA) and commu-
nity-acquired (CA) infections worldwide (now known as ST30-CA-
MRSA-IV, formerly Southwest Paciﬁc clone).17,18 Then suddenly, in
1959, penicillin-resistant S. aureus strains spread in hospitals and
in the community, accounting for around 80% of the total S. aureus
population. From this point on, the development of antimicrobial
resistance in this microorganism was rapid. Among the numerous
resistance determinants acquired by S. aureus, themostmanful one
was that to methicillin, synonymous now with multi-drug
resistance. Methicillin resistance emerged and diffused widely
all around the world by a clonal spreading, and the ‘age of MRSA’
commenced: we have faced 40 years ofMRSA and it is here to stay!
As already mentioned, since its appearance, MRSA prevalence
has constantly increased over time, especially in severe infections
in hospitalized patients, currently contributing to a high mortality
rate, above all in intensive care patients with BSIs. The ﬁrst
methicillin-resistant strain (MRSA strain COL), was isolated in a
patient in Colindale (London, UK) in 1961; this was a major global
defeat as, since their appearance, MRSA strains have been able to
evolve rapidly and create new clinical problems.19
The MRSA clones evolved from the MRSA COL strain (formerly
archaic clones) shared archaic molecular features and were
members of the same genetic lineage (CC8), including the major
penicillin-resistant methicillin-susceptible S. aureus (MSSA)
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circulated in the UK and in Europe from the 1970s to the 1980s, but
did not establish itself in the USA. The 1980swere characterized by
the appearance of gentamicin-resistant MRSA strains in several
countries, including the USA and Europe. In the following 20 years,
various international multidrug-resistant (MDR) MRSA lineages
acquired new SCCmec allotypes, homogeneously disseminated in
hospitals and in the community, due to their ability to cause
various infections, to persist and disseminate among diverse
geographic areas, including continents, thus making them
pandemic microorganisms.20
Methicillin resistance is associated with the acquisition of a
particular resistance island called SCCmec, an exogenous piece of
DNA, variable in size, that is absent from the methicillin-
susceptible strains. At least eight types of SCCmec have been
discriminated on the basis of the structure of their ccrA-B andmecA
complexes.21 SCCmec types I, II, III and VIII have been shown to
belong to hospital clones; while types IV, V, VI, and VII have been
identiﬁed as being typical of CA-MRSA. The latter group of
cassettes is much smaller than their hospital-related congeners, do
not carrymultiple antibiotic resistance genes, andmay be easier to
mobilize. These cassettes are associated, in the community strains,
to pathogenicity islands carryingmultiple staphylococcal exotoxin
genes, including the virus-encoded PVL toxin. Together, these
elements may make the organisms particularly ‘ﬁt’ and virulent.
MRSA strains are characterized by a multiple-resistance
phenotype as a consequence of accumulation and organization
in the SCCmec region of many resistance determinants over time;
this region can act as a hot-spot of integration for plasmids,
transposons, and insertion sequences. SCCmec-types and insertion/
deletion of other mobile genetic elements may be involved in
modulating the epidemic behavior of MRSA strains of similar
genetic background, independently of antibiotic usage. The
dynamics of these genotypic changes are strongly linked to shifts
in the levels of susceptibility tomany classes of antibiotics, and the
percentage of antibiotic resistance is associated with the
epidemiologic change and replacement of clones with speciﬁc
markers of resistance. Some examples could be the decrease in
resistance to tetracycline, rifampin, co-trimoxazole, and spectino-
mycin, due to the replacement of the MDR-MRSA clones ST247-
MRSA-IA, ST239-MRSA-IIIA, and ST247-MRSA-I/IA with the
tetracycline-susceptible ST228-MRSA-I clone, or the increased
level of susceptibility to gentamicin found in MRSA isolated in
Europe during 2000–2007, mainly due to the appearance of a
gentamicin-susceptible clone, belonging to ST22.
The widespread use of antibiotics has undoubtedly accelerated
the evolution of S. aureus, which, acquiring multiple resistance
genes, has become able to survive almost all antibiotic families, i.e.,
beta-lactams, macrolides, tetracyclines, ﬂuoroquinolones, and
aminoglycosides: this evolution versus more resistant phenotypes
has continued among the newer agents, including linezolid and
daptomycin. No antibiotics have been able to escape this correlation
between theuseof antibiotics and thedevelopmentof resistance:no
sooner has an antibiotic been introduced into clinical practice, than
some resistant strains have arisen. This is true for all classes of
antibioticswith the exception of glycopeptides (considered the gold
standard for MRSA therapy): in fact, resistance to these agents
among S. aureus strains took almost 40 years to be recognized.22
These recent increasing reports of reduced susceptibility to
glycopeptides due to their selective pressure from years of use, has
resulted in two different phenotypes: hVISA and vancomycin-
intermediate (VISA) strains. In contrast, high-level resistance
mediated by the vanA gene complex acquired by vancomycin-
resistant enterococci (VRE) has emerged in speciﬁc areas of the
world, above all in the USA in the area of Detroit. These resistant
strains have variable expression of resistance.17The diminished clinical usefulness of vancomycin is seen as one
of the most worrisome problems in many clinical settings and in
many countries.22 Although isolates with homogeneous resistance
to vancomycin (VISA; minimum inhibitory concentrations (MICs)
>4 mg/l) continue to be rare, there are increasing reports
describing the possible existence of heteroresistance sub-popula-
tions (hVISA), hidden often in strains with vancomycinMICs in the
1–2 mg/l range.23 Despite the fact that microbiological resistance
to vancomycin in S. aureus remains very rare, failure of vancomycin
therapy is already a clinical problem in hospitals, in ICUs,
especially in BSIs and infective endocarditis.22,24 In an Italian
study, an increase in vancomycin and teicoplanin MIC levels over
time has been described in HA-MRSA strains isolated from 1999 to
2007.10 More recently, a study (presented at the 49th Interscience
Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
Meeting, 2009) has demonstrated a high percentage of hVISA
strains among HA-MRSA isolated in Italy, possessing MICs to
vancomycin between 1 and 2 mg/l; these strains came from
documented bloodstream, pneumonia and skin-structure infec-
tions, during 2005–2006. They all belonged to the major
nosocomial clones, and some of them possessed characteristics
that resembled the classic VISA strain (Mu50), inducing us to
hypothesize that VISA behavior can be hidden with a MIC <4 mg/
l.10,20 It should be noted that not all studies have documented a
high percentage of hVISA in their MRSA isolates; but it is well
documented that infections by hVISA are highly predictive of
vancomycin treatment failure.25
In vitro detection of hVISA is insurmountable by current
standard methods, which employ inoculum levels that may be too
low; sophisticated and cumbersome tests, i.e., the population
analysis proﬁling/area under the curve test (PAP/AUC), not
routinely used in clinical microbiology laboratories, is required.
Recent attempts to identify hVISA bymacro-Etest have shown it to
be useful, but with the problem of sensitivity, and conﬁrmation is
still required using the PAP/AUC ratio test.20,22,23
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